1. 14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION. (April 2015) Authors: Komrokji, R.; Garcia-Manero, G.; Ades, L.; Laadem, A.; Vo, B.; Prebet, T.; Stamatoullas, A.; Boyd, T.; Delaunay, J.; Steensma, D.P.; Sekeres, M.A.; Beyne-Rauzy, O.; Zou, J.; Attie, K.M.; Sherman, M.L.; Fenaux, P.; List, A.F. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY. Issue 1 (April 2015) Authors: Steensma, D.; Abedi, M.; Bejar, R.; Cogle, C.; Foucar, K.; Garcia-Manero, G.; George, T.; Grinblatt, D.; Komrokji, R.; Maciejewski, J.; Pollyea, D.; Roboz, G.; Savona, M.; Scott, B.; Sekeres, M.; Thompson, M.; Sugrue, M.; Swern, A.; Nifenecker, M.; Erba, H. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 286 THE NOVEL FC-ENGINEERED CD33 ANTIBODY BI 836858 IMPROVES HEMATOPOIESIS BY PROTECTING HSC/HPC FROM ROS-MEDIATED DNA DAMAGE IN MDS. Issue 1 (April 2015) Authors: Eksioglu, E.A.; Chen, X.; Heider, K.H.; Rueter, B.; Burnette, A.; Wei, M.; McGraw, K.; Liu, J.; Basiorka, A.; Patel, P.; Lancet, J.; Komrokji, R.; List, A.; Wei, S. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 32 ACTIVATION OF REDOX-SENSITIVE INFLAMMASOMES UNDERLIES THE BIOLOGICAL PHENOTYPE OF MYELODYSPLASTIC SYNDROMES. (April 2015) Authors: Basiorka, A.; Mcgraw, K.; Eksioglu, E.; Chen, X.; Johnson, J.; Padron, E.; Komrokji, R.; Sokol, L.; Coll, R.; O'Neill, L.; Cooper, M.; Robertson, A.; Wei, S.; List, A. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 84 NOVEL MUTATIONS OF ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MIGHT BE ASSOCIATED WITH ADVANCE DISEASE IN MYELODYSPLASIA RELATED MYELOID NEOPLASM - ONE CENTER STUDY. Issue 1 (April 2015) Authors: Zhou, J.; Padron, E.; Nguyen, J.; Lancet, J.; Komrokji, R.; Bennett, J.; Moscinski, L.; List, A.; Zhang, L. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC). (April 2017) Authors: Nazha, A.; Sekeres, M.; Komrokji, R.; Steensma, D.; Kantarjian, H.; Roboz, G.; Fenaux, P.; Prebet, T.; Azarnia, N.; Zbyszewski, P.; Fruchtman, S.; Santini, V.; Silverman, L.; Platzbecker, U.; Garcia-Manero, G. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Evaluation of Salvage Induction Chemotherapy Regimens in Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure. (April 2017) Authors: Ball, B.; Komrokji, R.; Adès, L.; Sekeres, M.; DeZern, A.; Pleyer, L.; Vey, N.; Almeida, A.; Germing, U.; Cluzeau, T.; Platzbecker, U.; Gore, S.; Fenaux, P.; Prebet, T. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Maintenance Therapy with 5-Azacytidine after Allogeneic Hematopoietic Stem Cell Transplant for Myelodysplastic Syndrome Improves Survival. (April 2017) Authors: Mishra, A.; Al Ali, N.; Komrokji, R. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents. (April 2017) Authors: Park, S.; Hamel, J.F.; Toma, A.; Kelaidi, C.; Thepot, S.; Campelo Diez, M.; Santini, V.; Sekeres, M.; Balleari, E.; Kaivers, J.; Goetze, K.; Beyne-Rauzy, O.; Stamatoullas, A.; Kotsianidis, I.; Komrokji, R.; Steensma, D.; Germing, U.; Sanz, G.; Dreyfus, F.; Fenaux, P. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN-EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND JAK REARRANGEMENT. (23rd June 2022) Authors: Zhang, Y.; Nguyen, L.; Lu, C.; Wang, E.; Lauw, M.; Ball, S.; Dong, N.; Moscinski, L.; Chan, O.; Yun, S.; Sallman, D.; Sokol, L.; Shah, B.; Lancet, J.; Komrokji, R.; Kuykendall, A.; Padron, E.; Zhang, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗